View Older Stories View More Recent Stories

Feb 9, 2023 07:34AM Gilead Sciences' (GILD) Kite Announces Tecartus CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in R/R B-Cell ALL
Feb 9, 2023 07:15AM Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Feb 3, 2023 10:29AM Gilead Sciences (GILD) Announces FDA Approval of Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
Feb 3, 2023 10:29AM U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
Feb 1, 2023 08:35AM Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
Jan 30, 2023 09:00AM Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Jan 27, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Jan 19, 2023 04:05PM Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
Jan 5, 2023 01:50PM Gilead Sciences Again Named to Dow Jones Sustainability World Index
Jan 3, 2023 08:31AM Gilead Sciences (GILD) Announces Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
Jan 3, 2023 08:31AM Gilead Sciences (GILD) and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Jan 3, 2023 08:30AM Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Jan 3, 2023 08:30AM European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
Dec 27, 2022 04:30PM Gilead Sciences (GILD) to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics (JNCE)
Dec 27, 2022 04:30PM Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Dec 27, 2022 04:30PM Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
Dec 23, 2022 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 22, 2022 10:28AM Gilead Sciences (GILD) Sunlenca approved by FDA for HIV-1
Dec 22, 2022 10:27AM Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
Dec 20, 2022 08:00AM Gilead's (GILD) Kite Acquires Tmunity Therapeutics
Dec 20, 2022 08:00AM Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Dec 19, 2022 05:01PM Gilead (GILD) and Arcus (RCUS) Report Strong Interim Results of ARC-7 Study
Dec 19, 2022 05:00PM Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
Dec 19, 2022 05:00PM Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
Dec 12, 2022 11:00AM Gilead Sciences Again Named to Dow Jones Sustainability World Index
Dec 12, 2022 10:00AM New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
Dec 12, 2022 10:00AM Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Month
Dec 11, 2022 05:30PM Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma
Dec 9, 2022 08:17AM Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Dec 9, 2022 08:16AM Arcellx (ACLX) and Kite (GILD) Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
Dec 9, 2022 08:15AM Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
Dec 6, 2022 03:00PM New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
Nov 29, 2022 08:31AM Gilead Sciences (GILD) Announces EC Grants Expanded Marketing Authorization for Biktarvy for the Treatment of HIV in Pediatric Populations
Nov 29, 2022 08:30AM European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
Nov 28, 2022 08:31AM Gilead (GILD) and Arcus Biosciences (RCUS) Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
Nov 28, 2022 08:30AM Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer
Nov 28, 2022 08:30AM Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
Nov 15, 2022 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Nov 7, 2022 11:57AM Gilead, Kite in process of pausing Twitter advertising
Nov 3, 2022 09:15AM Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
Nov 2, 2022 07:01AM Gilead Sciences (GILD) Announces Approves Vemlidy for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Nov 2, 2022 07:01AM U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Nov 1, 2022 09:00AM Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
Oct 24, 2022 05:56AM Gilead Sciences (GILD) Reports Real-World Evidence Reinforcing the Use of Biktarvy for the Treatment of HIV
Oct 24, 2022 02:00AM Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities
Oct 20, 2022 09:02AM Gilead Sciences (GILD) Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
Oct 20, 2022 09:00AM Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
Oct 18, 2022 08:35AM Gilead Sciences (GILD) Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022
Oct 18, 2022 08:30AM Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022
Oct 17, 2022 04:31PM Gilead(GILD) Announces Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
View More Recent Stories View Older Stories